Mast Therapeutics (MSTX) Said Clinical QT Study Of MST-188 Met Primary Endpoint

July 23, 2013 8:11 AM EDT Send to a Friend
Get Alerts MSTX Hot Sheet
Trade MSTX Now!
Join SI Premium – FREE
Mast Therapeutics, Inc. (NYSE: MSTX) announced results of its thorough QT/QTc study of MST-188, an investigational agent being developed to treat serious or life-threatening diseases with significant unmet needs, such as sickle cell disease and acute limb ischemia. The study met its primary endpoint and demonstrated that, based on analysis of electrocardiograms, MST-188 did not have an adverse effect on cardiac repolarization, as measured by prolongation of the QT interval. MST-188 was generally well-tolerated at both therapeutic and supratherapeutic doses.

Brian M. Culley, Chief Executive Officer, said: "I congratulate our clinical operations team for successfully executing the first clinical study of MST-188 since we acquired the program. The results from this trial augment the safety data supporting MST-188 and our belief that MST-188 will demonstrate a favorable risk/benefit profile in our on-going Phase 3 study in sickle cell disease, as well as our planned Phase 2 study in acute limb ischemia."


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Add Your Comment